X4 Pharmaceuticals (XFOR) to Release Earnings on Thursday

Key Points

• Q1 2026 earnings: X4 will report before the market opens on Thursday, May 7, with analysts expecting EPS of ($0.20) and revenue of $3.20 million.
• Recent performance & outlook: The company beat prior-quarter estimates (reported ($0.22) vs. est. ($0.36) and $2.57M revenue vs. $1.68M) but still shows negative margins and ROE, and analysts project about ($1) EPS for the current and next fiscal year.
• Market snapshot: Shares opened at $4.10 with a $372.8M market cap; consensus rating is "Hold" with a $8.50 price target and roughly 72% institutional ownership.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) is projected to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.20) per share and revenue of $3.20 million for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 4, 2026 at 9:30 AM ET.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last issued its earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.14. The business had revenue of $2.57 million for the quarter, compared to analysts' expectations of $1.68 million. X4 Pharmaceuticals had a negative return on equity of 115.27% and a negative net margin of 225.55%. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

X4 Pharmaceuticals Trading Down 0.5%

XFOR opened at $4.10 on Thursday. X4 Pharmaceuticals has a one year low of $1.35 and a one year high of $4.83. The stock has a market capitalization of $372.77 million, a PE ratio of -0.94 and a beta of 0.32. The business's 50 day moving average price is $3.95 and its 200 day moving average price is $3.78. The company has a debt-to-equity ratio of 0.41, a quick ratio of 9.98 and a current ratio of 10.16.

Wall Street Analyst Weigh In

XFOR has been the topic of a number of recent analyst reports. Wall Street Zen upgraded X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Guggenheim initiated coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They issued a "buy" rating and a $12.00 price objective on the stock. Finally, Weiss Ratings upgraded X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, April 24th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $8.50.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in XFOR. Squarepoint Ops LLC purchased a new stake in X4 Pharmaceuticals in the fourth quarter valued at approximately $50,000. Two Sigma Investments LP purchased a new stake in X4 Pharmaceuticals in the third quarter valued at approximately $47,000. Stifel Financial Corp purchased a new stake in X4 Pharmaceuticals in the fourth quarter valued at approximately $82,000. Virtu Financial LLC purchased a new stake in X4 Pharmaceuticals in the fourth quarter valued at approximately $90,000. Finally, Man Group plc purchased a new stake in X4 Pharmaceuticals in the fourth quarter valued at approximately $97,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company's lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström's macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.